dm+d
Unassigned
New Medicines
Bullous pemphigoid
Information
New molecular entity
Akari Therapeutics
Akari Therapeutics
Development and Regulatory status
Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Yes
Yes
Category
Inhibitor of two cytokines, complement C5 and lipid mediator leukotriene B4 (LTB4)
BP is a severe autoimmune inflammatory blistering skin disease. It is most common in the elderly and primarily treated with steroids and immunosuppressants. It affects around 100,000 people in the UK and Europe. There is evidence that both complement component C5 and LTB4 have a central role in the disease [1].
Bullous pemphigoid
Subcutaneous injection